# Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients

> **NCT01543464** · PHASE2 · TERMINATED · sponsor: **Inge Marie Svane** · enrollment: 41 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Chemotherapy: Temozolomide

## Key facts

- **NCT ID:** NCT01543464
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Diminished rectruitment
- **Last updated:** 2018-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01543464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01543464, "Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01543464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*